切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2019, Vol. 08 ›› Issue (01) : 72 -75. doi: 10.3877/cma.j.issn.2095-3232.2019.01.017

所属专题： 文献；

基础研究

TFAP 4在肝细胞癌中表达及其与预后的关系
黄涛1, 沈露俊1, 陈奇峰1, 李旺1, 吴沛宏1,†()   
  1. 1. 510060　广州，中山大学肿瘤防治中心微创介入科　华南肿瘤学国家重点实验室　肿瘤医学协同创新中心
  • 收稿日期:2018-10-25 出版日期:2019-02-10
  • 通信作者: 吴沛宏
  • 基金资助:
    广东省公益研究与能力建设专项资金项目(2014A020212532)

TFAP 4 expression in hepatocellular carcinoma and its relationship with clinical prognosis

Tao Huang1, Lujun Shen1, Qifeng Chen1, Wang Li1, Peihong Wu1,†()   

  1. 1. Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
  • Received:2018-10-25 Published:2019-02-10
  • Corresponding author: Peihong Wu
  • About author:
    Corresponding author: Wu Peihong, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

黄涛, 沈露俊, 陈奇峰, 李旺, 吴沛宏. TFAP 4在肝细胞癌中表达及其与预后的关系[J]. 中华肝脏外科手术学电子杂志, 2019, 08(01): 72-75.

Tao Huang, Lujun Shen, Qifeng Chen, Wang Li, Peihong Wu. TFAP 4 expression in hepatocellular carcinoma and its relationship with clinical prognosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2019, 08(01): 72-75.

目的

探讨转录因子激活增强子结合蛋白4（TFAP 4）在肝细胞癌（HCC）中的表达及其与患者预后的关系。

方法

标本来源于2007年12月至2014年12月中山大学肿瘤防治中心的116例术后病理检查确诊为HCC患者。患者均签署知情同意书，符合医学伦理学规定。其中男103例，女13例；年龄22～75岁，中位年龄44岁。免疫组化法检测HCC组织TFAP 4的表达量，TFAP 4蛋白表达与临床病理参数之间的关系分析采用χ2检验。生存分析采用Kaplan-Meier曲线和Log-rank检验。Cox比例风险回归模型分析TFAP 4在HCC组织中的表达与预后的关系。

结果

TFAP 4高表达者54例，低表达者62例，其表达与患者临床病理参数无相关性（P>0.05）。TFAP 4高表达患者的无瘤生存和总体生存均更差（χ2=11.030，4.269；P<0.05）。Cox回归分析显示，HBsAg阳性是影响HCC患者无瘤生存的独立危险因素（HR=4.722，95%CI：1.469～19.446，P<0.05），而TFAP 4高表达是影响HCC患者无瘤生存和总体生存的独立危险因素（HR=2.437，2.598；95%CI：1.352～4.394，1.036～6.515；P<0.05）。

结论

TFAP 4高表达是影响HCC患者无瘤生存和总体生存的独立危险因素，TFAP 4高表达患者预后较差。TFAP 4可作为判断HCC患者预后的生物学标志物。

关键词: 癌，肝细胞, TFAP4, 预后, 免疫组织化学
Objective

To investigate the expression of transcription factor activating enhancer-binding protein 4 (TFAP 4) in hepatocellular carcinoma (HCC) and its relationship with the clinical prognosis of HCC patients.

Methods

The tissue specimens were obtained from 116 HCC patients diagnosed by pathological examination in Sun Yat-sen University Cancer Center from December 2007 to December 2014. The informed consents of all patients were obtained and the local ethical committee approval was received. Among 116 patients, 103 were male and 13 were female, aged 22-75 years with a median age of 44 years. The expression of TFAP 4 in HCC tissues was measured by immunohistochemical staining. The relationship between the expression of TFAP 4 protein and clinicopathological parameters was analyzed by Chi-square test. The survival analysis was conducted by Kaplan-Meier survival curve and Log-rank test. The relationship between TFAP 4 expression and clinical prognosis of HCC patients was analyzed by Cox's proportional hazards model.

Results

TFAP 4 was highly expressed in 54 patients and lowly expressed in 62. The expression of TFAP 4 was not associated with clinicopathological features (P>0.05). The tumor-free survival and overall survival of patients with high expression of TFAP 4 were worse than those with low expression of TFAP 4 (χ2=11.030, 4.269; P<0.05). Cox's regression analysis demonstrated that positive HBsAg was an independent risk factor for the tumor-free survival of HCC patients (HR=4.722, 95%CI: 1.469-19.446, P<0.05), whereas high expression of TFAP 4 was an independent risk factor for tumor-free survival and overall survival of HCC patients (HR=2.437, 2.598; 95%CI: 1.352-4.394, 1.036-6.515; P<0.05).

Conclusions

High expression of TFAP 4 is an independent risk factor for tumor-free survival and overall survival of HCC patients. Patients with high expression of TFAP 4 have poorer clinical prognosis. TFAP 4 can be used as a biomarker to predict the clinical prognosis of HCC patients.

Key words: Carcinoma, hepatocellular, TFAP4, Prognosis, Immunohistochemistry
表1 TFAP4在HCC中的表达与临床病理参数的关系（例）
参数 例数 TFAP 4表达 χ2值 P值
高表达 低表达
年龄 ? ? ? 0.417 0.518
? < 60岁 96 46 50 ? ?
? ≥60岁 20 8 12 ? ?
性别 ? ? ? 3.243 0.072
? 男 103 51 52 ? ?
? 女 13 3 10 ? ?
HBsAg ? ? ? 0.231 0.631
? 阴性 17 7 10 ? ?
? 阳性 99 47 52 ? ?
AFP ? ? ? 2.260 0.133
? < 400 μg/L 81 34 47 ? ?
? ≥400 μg/L 35 20 15 ? ?
肿瘤直径 ? ? ? ? ?
? < 5 cm 72 35 37 0.324 0.569
? ≥5 cm 44 19 25 ? ?
肝包膜 ? ? ? 1.724 0.189
? 未侵犯 78 33 45 ? ?
? 侵犯 38 21 17 ? ?
脉管侵犯 ? ? ? 3.346 0.067
? 无 105 46 59 ? ?
? 有 11 8 3 ? ?
BCLC分期 ? ? ? 0.718 0.397
? A期 102 46 56 ? ?
? B期 14 8 6 ? ?
病理分级 ? ? ? 0.327 0.568
? Ⅰ～Ⅱ级 99 45 54 ? ?
? Ⅲ～Ⅳ级 17 9 8 ? ?
图1 TFAP 4的表达与HCC患者预后的Kaplan-Meier生存曲线
[1]
Petrick JL, Braunlin M, Laversanne M, et al. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007[J]. Int J Cancer, 2016, 139(7):1534-1545.
[2]
European Association for the Study of the Liver, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236.
[3]
Fan ST, Mau Lo C, Poon RT, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience[J]. Ann Surg, 2011, 253(4):745-758.
[4]
Jeon Y, Kim H, Jang ES, et al. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients[J]. APMIS, 2016, 124(3):208-215.
[5]
Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma[J]. Clin Chim Acta, 2001, 313(1/2):15-19.
[6]
Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12):1687-1693.
[7]
Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma[J]. Gastroenterology, 2009, 137(1):110-118.
[8]
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2010, 16(4):418-424.
[9]
Jones S. An overview of the basic helix-loop-helix proteins[J]. Genome Biol, 2004, 5(6):226.
[10]
Jackstadt R, Röh S, Neumann J, et al. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer[J]. J Exp Med, 2013, 210(7):1331-1350.
[11]
Xinghua L, Bo Z, Yan G, et al. The overexpression of AP-4 asa prognostic indicator for gastric carcinoma[J]. Med Oncol, 2012, 29(2):871-877.
[12]
Wei J, Yang P, Zhang T, et al. Overexpression of transcription factor activating enhancer binding protein 4 (TFAP4) predicts poor prognosis for colorectal cancer patients[J]. Exp Ther Med, 2017, 14(4):3057-3061.
[13]
Chen C, Cai Q, He W, et al. AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin[J]. Cell Death Dis, 2017, 8(10):e3060.
[14]
Gong H, Han S, Yao H, et al. AP4 predicts poor prognosis in non-small cell lung cancer[J]. Mol Med Rep, 2014, 10(1):336-340.
[15]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[16]
Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma[J]. Clin Liver Dis, 2001, 5(1):145-159.
[17]
Jung P, Menssen A, Mayr D, et al. AP4 encodes a c-MYC-inducible repressor of p21[J]. Proc Natl Acad Sci, 2008, 105(39):15046-15051.
[18]
Kouraklis G, Katsoulis IE, Theocharis S, et al. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?[J]. Dig Dis Sci, 2009, 54(5):1015-1020.
[19]
Wang L, Meng Y, Xu JJ, et al. The transcription factor AP4 promotes oncogenic phenotypes and cisplatin resistance by regulating LAPTM4B expression[J]. Mol Cancer Res, 2018, 16(5):857-868.
[20]
Chen S, Chiu SK. AP4 activates cell migration and EMT mediated by p53 in MDA-MB-231 breast carcinoma cells[J]. Mol Cell Biochem, 2015, 407(1/2):57-68.
[1] 应康, 杨璨莹, 刘凤珍, 陈丽丽, 刘燕娜. 左心室心肌应变对无症状重度主动脉瓣狭窄患者的预后评估价值[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 581-587.
[2] 武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲. 超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 631-635.
[3] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[4] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[5] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[6] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[7] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[8] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[9] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[10] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[11] 卢艳军, 马健, 白鹏宇, 郭凌宏, 刘海义, 江波, 白文启, 张毅勋. 纳米碳在腹腔镜直肠癌根治术中253组淋巴结清扫的临床效果[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 473-477.
[12] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[13] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[14] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号